Table 1.
Key clinical trials of the combination of different ICIs.
| Study | Indication | Phase | Treatment (n) | Efficacy endpoints | Grade 3/4 AEs | Reference | ||
|---|---|---|---|---|---|---|---|---|
| RR | PFS | OS | ||||||
| CheckMate-227 (NCT02477826) | NSCLC | 3 | Ipilimumab + nivolumab (583) | 35.9% | / | 17.1 m | 32.8% | [235] |
| Chemotherapy (583) | 30.0% | / | 13.9 m | 36.0% | ||||
| CheckMate-214 (NCT02231749) | RCC | 3 | Ipilimumab + nivolumab (550) | 42% | 11.6 m | 18-month OS rate 75% vs. 60% | 46% | [7] |
| Sunitinib (546) | 27% | 8.4 m | 63% | |||||
| CheckMate-067 (NCT01844505) | Melanoma | 3 | Nivolumab + ipilimumab (314) | 58.3% | 11.5 m | 72.1 | 59% | [6] |
| Nivolumab (316) | 44.9% | 6.9 m | 36.9 | 24% | ||||
| Ipilimumab (315) | 19.0% | 2.9 m | 19.9 | 28% | ||||
| CheckMate-069 (NCT01927419) | Melanoma | 2 | Nivolumab + ipilimumab (95) | 59% | 2-year PFS rate 51.3% vs. 12.0% | 2-year OS rate 63.8% vs. 53.6% | 54% | [236] |
| Ipilimumab (47) | 11% | 20% | ||||||
| CheckMate-142 (NCT02060188) | MMR/MSI-H CRC | 2 | Nivolumab + ipilimumab (119) | 55% | 1-year PFS rate 71% | 1-year OS rate 85% | 32% | [223] |
| ARCTIC (NCT02352948) | NSCLC | 3 | Durvaluma + tremelimumab (174) | 26% | 3.5 m | 11.5 m | 74% | [237] |
| Standard of care (118) | 8% | 3.5 m | 8.7 m | 57% | ||||
| CONDOR (NCT02319044) | HNSCC | 2 | Durvalumab + tremelimumab (133) | 7.8% | 2.0 m | 7.6 m | 15.8% | [238] |
| Durvalumab (67) | 9.2% | 1.9 m | 6.0 m | 12.3% | ||||
| Tremelimumab (67) | 1.6% | 1.9 m | 5.5 m | 16.9% | ||||
| DANUBE (NCT02516241) | Urothelial carcinoma | 3 | Durvalumab + tremelimumab (342) | 36% | 3.7 m | 15.1 m | 27% | [239] |
| Chemotherapy (344) | 49% | 6.7 m | 12.1 m | 60% | ||||
| NCT02919683 | Oral Cavity Squamous Cell Carcinoma | 2 | Nivolumab + ipilimumab (15) | 38% | / | / | 33.3% | [240] |
| Nivolumab (14) | 13% | / | / | 14.3% | ||||
| CheckMate-650 (NCT02985957) | Prostate Cancer | 2 | Nivolumab + ipilimumab (pre-chemotherapy; 45) | 25% | 5.5 m | 19.0 m | 17.6% | [205] |
| Nivolumab + ipilimumab (post-chemotherapy; 45) | 10% | 3.8 m | 15.2 m | 10.0% | ||||
| CheckMate-743 (NCT02899299) | Malignant pleural mesothelioma | 3 | Nivolumab + ipilimumab (303) | 32% | 6.8 m | 18.1 m | 30% | [241] |
| Chemotherapy (302) | 8% | 7.2 m | 14.1 m | 32% | ||||